Fortis Healthcare

Fortis Healthcare delivered a strong Q3 FY26 with consolidated revenue of ₹2,265 croreCurrent reported value: ₹2,265 crore. No comparable prior figure is available in the source record. (+17.5Current reported value: 17.5. No comparable prior figure is available in the source record.% YoY) and EBITDA margin expansion of 290 bps to 22.3%Current reported value: 290 bps to 22.3%. No comparable prior figure is available in the source record., driven by hospital business growth of 19.4% and diagnostics margin recovery to 23.1%. PAT declined to ₹197Current reported value: 197. No comparable prior figure is available in the source record. crore due to a one-off expense of ₹55 crore for new labor codes. Hospital occupancy remained steady at 67%Current 67%. Reported change: Flat YoY., while ARPOB grew 4.5% to ₹2.56 lakhCurrent ₹2.56 lakh. Reported change: +4.5% YoY., supported by a 52% surge in robotic surgeries. The diagnostics business saw 8.3% revenue growth and a 870 bps margin improvement. Management guided for continued growth trajectory with brownfield expansion of ~400 beds in FY27, led by the fMRI facility. The People Tree acquisition in Bengaluru adds 125 beds with expansion potential to 300. Risks include integration challenges at Glenagles and potential dilution from IHH's planned equity infusion.